- 現金殖利率: N/A、總殖利率: 0、5年平均現金配發率: 17.18%
- 要留意資產負債表的未分配盈餘和配息能力, 如果為負值, 可能會無法發放股利
- 股利有2個稅要支出, 分別是綜合所得稅和健保補充保費(單筆股利達2萬元以上, 課2.11%)
| EPS YoY | 現金股利 YoY | 股票股利 YoY | 現金配發率 YoY | 股票配發率 YoY | 全部配發率 YoY | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2023 (10) | -0.51 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 | 0.00 | 0 |
| 2022 (9) | 0.70 | -80.0 | 0.10 | -50.0 | 0.00 | 0 | 14.29 | 150.0 | 0.00 | 0 | 14.29 | 150.0 |
| 2021 (8) | 3.50 | 366.67 | 0.20 | 100.0 | 0.00 | 0 | 5.71 | -57.14 | 0.00 | 0 | 5.71 | -57.14 |
| 2020 (7) | 0.75 | -37.5 | 0.10 | -50.0 | 0.00 | 0 | 13.33 | -20.0 | 0.00 | 0 | 13.33 | -20.0 |
| 2019 (6) | 1.20 | -71.29 | 0.20 | -86.67 | 0.00 | 0 | 16.67 | -53.56 | 0.00 | 0 | 16.67 | -75.12 |
| 2018 (5) | 4.18 | 13.28 | 1.50 | -16.67 | 1.30 | 30.0 | 35.89 | -26.44 | 31.10 | 14.76 | 66.99 | -11.72 |
| 2017 (4) | 3.69 | 47.6 | 1.80 | 20.0 | 1.00 | 100.0 | 48.78 | -18.7 | 27.10 | 35.5 | 75.88 | -5.15 |
| 2016 (3) | 2.50 | 72.41 | 1.50 | 30.43 | 0.50 | 0 | 60.00 | -24.35 | 20.00 | 0 | 80.00 | 0.87 |
| EPS QoQ YoY | 本業EPS QoQ YoY | 累計EPS QoQ YoY | |||||||
|---|---|---|---|---|---|---|---|---|---|
| 24Q3 (20) | 0.00 | 100.0 | -100.0 | 0.11 | 147.83 | 1200.0 | -1.70 | 0.58 | -400.0 |
| 24Q2 (19) | -1.46 | -484.0 | -294.59 | -0.23 | -91.67 | 41.03 | -1.71 | -584.0 | -388.57 |
| 24Q1 (18) | -0.25 | -47.06 | -1350.0 | -0.12 | -340.0 | -200.0 | -0.25 | 50.98 | -1350.0 |
| 23Q4 (17) | -0.17 | -1800.0 | -112.5 | 0.05 | 600.0 | -87.18 | -0.51 | -50.0 | -172.86 |
| 23Q3 (16) | 0.01 | 102.7 | -98.25 | -0.01 | 97.44 | -101.85 | -0.34 | 2.86 | -143.59 |
| 23Q2 (15) | -0.37 | -1950.0 | 0 | -0.39 | -425.0 | -333.33 | -0.35 | -1850.0 | -266.67 |
| 23Q1 (14) | 0.02 | 125.0 | -90.91 | 0.12 | -69.23 | -14.29 | 0.02 | -97.14 | -90.91 |
| 22Q4 (13) | -0.08 | -114.04 | -103.83 | 0.39 | -27.78 | -81.94 | 0.70 | -10.26 | -80.0 |
| 22Q3 (12) | 0.57 | 0 | -14.93 | 0.54 | 700.0 | 5.88 | 0.78 | 271.43 | -44.68 |
| 22Q2 (11) | 0.00 | -100.0 | -100.0 | -0.09 | -164.29 | -147.37 | 0.21 | -4.55 | -72.0 |
| 22Q1 (10) | 0.22 | -89.47 | -50.0 | 0.14 | -93.52 | -69.57 | 0.22 | -93.71 | -50.0 |
| 21Q4 (9) | 2.09 | 211.94 | 309.8 | 2.16 | 323.53 | 285.71 | 3.50 | 148.23 | 366.67 |
| 21Q3 (8) | 0.67 | 123.33 | 28.85 | 0.51 | 168.42 | -7.27 | 1.41 | 88.0 | 487.5 |
| 21Q2 (7) | 0.30 | -31.82 | 230.43 | 0.19 | -58.7 | 173.08 | 0.75 | 70.45 | 377.78 |
| 21Q1 (6) | 0.44 | -13.73 | 1200.0 | 0.46 | -17.86 | 483.33 | 0.44 | -41.33 | 1200.0 |
| 20Q4 (5) | 0.51 | -1.92 | 234.21 | 0.56 | 1.82 | 286.67 | 0.75 | 212.5 | -37.5 |
| 20Q3 (4) | 0.52 | 326.09 | 0.0 | 0.55 | 311.54 | 0.0 | 0.24 | 188.89 | 0.0 |
| 20Q2 (3) | -0.23 | -475.0 | 0.0 | -0.26 | -116.67 | 0.0 | -0.27 | -575.0 | 0.0 |
| 20Q1 (2) | -0.04 | 89.47 | 0.0 | -0.12 | 60.0 | 0.0 | -0.04 | -103.33 | 0.0 |
| 19Q4 (1) | -0.38 | 0.0 | 0.0 | -0.30 | 0.0 | 0.0 | 1.20 | 0.0 | 0.0 |
| 年/月 | 營收 | 月增率(%) | 去年同期年增率(%) | 累計營收 | 累計營收年增率(%) | 近三月累計營收 | 存貨銷售比 | 自結稅前EPS | 自結稅前累計EPS | 備註(年增率變動50%需說明原因) |
|---|---|---|---|---|---|---|---|---|---|---|
| 2024/10 | 14.9 | 13.55 | -13.55 | 155.94 | 2.92 | 44.36 | N/A | - | ||
| 2024/9 | 13.12 | -19.71 | -17.3 | 141.04 | 5.03 | 50.79 | 0.69 | - | ||
| 2024/8 | 16.34 | -23.38 | 4.51 | 127.92 | 8.02 | 51.14 | 0.68 | - | ||
| 2024/7 | 21.33 | 58.38 | 36.54 | 111.57 | 8.56 | 51.06 | 0.69 | - | ||
| 2024/6 | 13.47 | -17.16 | 12.22 | 90.24 | 3.54 | 46.01 | 0.68 | - | ||
| 2024/5 | 16.26 | -0.14 | 11.13 | 76.78 | 2.15 | 46.99 | 0.66 | - | ||
| 2024/4 | 16.28 | 12.68 | 15.24 | 60.52 | 0.0 | 44.37 | 0.7 | - | ||
| 2024/3 | 14.45 | 5.93 | -5.06 | 44.23 | -4.65 | 44.23 | 0.8 | - | ||
| 2024/2 | 13.64 | -15.49 | -14.58 | 29.78 | -4.45 | 42.37 | 0.84 | - | ||
| 2024/1 | 16.14 | 28.27 | 6.18 | 16.14 | 6.18 | 43.39 | 0.82 | - | ||
| 2023/12 | 12.58 | -14.2 | -21.15 | 178.77 | -23.44 | 44.49 | 0.62 | - | ||
| 2023/11 | 14.67 | -14.9 | -16.63 | 166.18 | -23.61 | 47.77 | 0.58 | - | ||
| 2023/10 | 17.24 | 8.63 | -23.22 | 151.51 | -24.22 | 48.74 | 0.57 | - | ||
| 2023/9 | 15.87 | 1.46 | -25.41 | 134.28 | -24.35 | 47.12 | 0.56 | - | ||
| 2023/8 | 15.64 | 0.09 | -29.43 | 118.41 | -24.2 | 43.26 | 0.61 | - | ||
| 2023/7 | 15.62 | 30.17 | -33.53 | 102.78 | -23.34 | 42.25 | 0.63 | - | ||
| 2023/6 | 12.0 | -17.97 | -37.1 | 87.15 | -21.17 | 40.76 | 0.72 | - | ||
| 2023/5 | 14.63 | 3.54 | -25.59 | 75.15 | -17.85 | 43.98 | 0.67 | - | ||
| 2023/4 | 14.13 | -7.17 | -28.3 | 60.52 | -15.73 | 45.32 | 0.65 | - | ||
| 2023/3 | 15.22 | -4.69 | -15.99 | 46.39 | -10.97 | 46.39 | 0.71 | - | ||
| 2023/2 | 15.97 | 5.06 | 3.35 | 31.17 | -8.3 | 47.13 | 0.7 | - | ||
| 2023/1 | 15.2 | -4.75 | -18.02 | 15.2 | -18.02 | 48.76 | 0.68 | - | ||
| 2022/12 | 15.96 | -9.28 | 21.86 | 233.51 | -5.21 | 56.01 | 0.57 | - | ||
| 2022/11 | 17.59 | -21.63 | -62.88 | 217.55 | -6.73 | 61.32 | 0.52 | 2021年11月與Genzyme 就被授權之歐洲及美國專利權所生之歐洲與美國權利金爭議達成和解，故於2021年11月認列權利金收入。 | ||
| 2022/10 | 22.45 | 5.54 | 34.31 | 199.95 | 7.58 | 65.88 | 0.49 | - | ||
| 2022/9 | 21.27 | -4.0 | 32.08 | 177.5 | 4.94 | 66.93 | 0.54 | - | ||
| 2022/8 | 22.16 | -5.71 | 1.17 | 156.23 | 2.08 | 64.74 | 0.56 | - | ||
| 2022/7 | 23.5 | 23.18 | 25.86 | 134.07 | 2.23 | 62.25 | 0.58 | - | ||
| 2022/6 | 19.08 | -2.97 | -2.4 | 110.57 | -1.68 | 58.45 | 0.57 | - | ||
| 2022/5 | 19.66 | -0.23 | 3.72 | 91.49 | -1.53 | 57.49 | 0.58 | - | ||
| 2022/4 | 19.71 | 8.78 | -2.84 | 71.82 | -2.88 | 53.28 | 0.63 | - | ||
| 2022/3 | 18.12 | 17.25 | -3.36 | 52.11 | -2.89 | 52.11 | 0.59 | - | ||
| 2022/2 | 15.45 | -16.67 | -1.72 | 34.0 | -2.64 | 47.09 | 0.66 | - | ||
| 2022/1 | 18.54 | 41.58 | -3.4 | 18.54 | -3.4 | 79.04 | 0.39 | - | ||
| 2021/12 | 13.1 | -72.36 | -26.33 | 246.35 | 43.86 | 77.21 | 0.36 | - | ||
| 2021/11 | 47.4 | 183.55 | 191.69 | 233.26 | 52.0 | 80.22 | 0.35 | 與Genzyme 就被授權之歐洲及美國專利權所生之歐洲與美國權利金爭議達成和解，故本月認列權利金收入。 | ||
| 2021/10 | 16.72 | 3.79 | 8.93 | 185.86 | 35.45 | 54.72 | 0.51 | - | ||
| 2021/9 | 16.1 | -26.46 | 3.94 | 169.14 | 38.79 | 56.68 | 0.41 | - | ||
| 2021/8 | 21.9 | 17.28 | 14.72 | 153.04 | 43.87 | 60.12 | 0.39 | - | ||
| 2021/7 | 18.67 | -4.47 | 27.85 | 131.14 | 50.24 | 57.18 | 0.41 | 109年受到疫情影響停工，銷量減少，110年疫情趨緩，銷量增加，致營收增加。 | ||
| 2021/6 | 19.55 | 3.12 | 66.33 | 112.46 | 54.74 | 58.79 | 0.35 | 109年因疫情影響，營收減少，110年因疫情趨緩，營收增加 | ||
| 2021/5 | 18.96 | -6.54 | 109.32 | 92.91 | 52.51 | 57.99 | 0.36 | 109年因疫情影響，營收減少，110年因疫情趨緩，營收增加 | ||
| 2021/4 | 20.29 | 8.2 | 181.42 | 73.96 | 42.59 | 54.76 | 0.38 | 109年受到疫情影響停工，銷量減少，110年疫情趨緩，銷量增加，致營收增加。 | ||
| 2021/3 | 18.75 | 19.24 | 22.78 | 53.67 | 20.18 | 53.67 | 0.53 | - | ||
| 2021/2 | 15.72 | -18.1 | 7.06 | 34.92 | 18.82 | 52.7 | 0.54 | - | ||
| 2021/1 | 19.2 | 7.98 | 30.57 | 19.2 | 30.57 | 53.23 | 0.54 | - | ||
| 2020/12 | 17.78 | 9.41 | 903.0 | 171.24 | -23.11 | 49.37 | 0.45 | 本月營收較同期增加，係108年12月當期調減108年第2季到第4季未收到之權利金收入所致。 | ||
| 2020/11 | 16.25 | 5.89 | -2.59 | 153.46 | -30.54 | 47.09 | 0.47 | - | ||
| 2020/10 | 15.34 | -0.95 | -11.36 | 137.21 | -32.82 | 49.93 | 0.44 | - | ||
| 2020/9 | 15.49 | -18.84 | -17.91 | 121.86 | -34.81 | 49.19 | 0.47 | - | ||
| 2020/8 | 19.09 | 30.7 | -20.95 | 106.37 | -36.71 | 45.45 | 0.51 | - | ||
| 2020/7 | 14.61 | 24.26 | -30.81 | 87.28 | -39.35 | 35.41 | 0.65 | - | ||
| 2020/6 | 11.75 | 29.77 | -41.88 | 72.67 | -40.82 | 28.02 | 1.0 | - | ||
| 2020/5 | 9.06 | 25.63 | -57.3 | 60.92 | -40.61 | 31.53 | 0.89 | 營收較去年同期減少，係因受到疫情影響，銷量減少所致 | ||
| 2020/4 | 7.21 | -52.79 | -65.14 | 51.87 | -36.26 | 37.16 | 0.75 | 營收較上期、去年同期減少，係因受疫情停工影響，銷量減少，以致營收減少 | ||
| 2020/3 | 15.27 | 3.97 | -27.21 | 44.66 | -26.41 | 44.66 | 0.66 | - | ||
| 2020/2 | 14.69 | -0.11 | -18.56 | 29.39 | -25.99 | 31.16 | 0.95 | - | ||
| 2020/1 | 14.7 | 729.44 | -32.18 | 14.7 | -32.18 | 33.16 | 0.89 | - | ||
| 2019/12 | 1.77 | -89.37 | -90.96 | 222.71 | -8.83 | 0.0 | N/A | 係原合併營收公告數與會計師查核數差異，請參閱109/3/20序號5重訊之說明 | ||
| 2019/11 | 16.68 | -3.63 | -19.07 | 220.94 | -1.66 | 0.0 | N/A | - |
